Billionaire Vivek Ramaswamy's net worth has seen a significant surge, increasing by over 80% to $1.8 billion by November 2025, according to a Forbes report. This substantial growth occurred during a pivotal nine-month period for the Indian-American businessman-turned-politician, even as he navigated various political transitions.

Ramaswamy's political journey in 2025 included dropping out of the United States Presidential race in late 2024, being sidelined from Elon Musk's Department of Government Efficiency (DOGE) in January 2025, and subsequently launching his campaign for the Ohio Governor's office in February 2025. Announcing his gubernatorial campaign in Cincinnati, Ramaswamy articulated a vision for a "new golden age" for the U.S., pledging to lead Ohio to become the top state for capitalism and meritocracy.

The Forbes report highlighted that Ramaswamy's net worth jumped from approximately $1 billion in March 2025 to $1.8 billion by November of the same year. A spokesperson for the Republican politician confirmed the general accuracy of these figures. A significant portion of this increase is attributed to Ramaswamy's substantial stake in his pharmaceutical company, Roivant Sciences. Roivant's business model involves developing and commercializing experimental drugs that have been previously abandoned by major pharmaceutical companies, thereby unlocking their inherent value.

While Ramaswamy stepped down from his executive role at Roivant Sciences in February 2023 in anticipation of his U.S. presidential bid, he remains one of the company's largest shareholders, holding a 7.17% stake, as reported by the Washington Post. Prior to his departure as Chairman (a role he assumed in 2021), Roivant sold five subsidiaries to the Japanese conglomerate Sumitomo for $3 billion in 2019, leading Ramaswamy (then CEO) to declare $170 million in capital gains for 2020.

Further enhancing his wealth, Roivant Sciences went public via a Special Purpose Acquisition Company (SPAC) in 2021. In October 2023, the company sold another subsidiary to Swiss pharma giant Roche for $7.1 billion, which propelled its stock up by 34% by year-end. News of positive trials for brepocitinib, a drug targeting the autoimmune disease dermatomyositis, which causes muscle weakness and skin lesions, also contributed to the stock's gains. These upward movements solidified Ramaswamy's billion-dollar fortune, largely tied to his 49 million shares in Roivant.

In addition to Roivant, Vivek Ramaswamy's spokesperson confirmed his ownership stake in Chapter, a company dedicated to assisting senior citizens with navigating Medicare. In 2020, Chapter was valued at $1.5 billion, and sources told Forbes that Ramaswamy's 6.7% stake is estimated to be worth approximately $100 million.

The Republican's campaign for Ohio governor has also demonstrated successful fundraising efforts. As of July 2025, Vivek Ramaswamy had raised $9.7 million, according to filings with the Ohio secretary of state. His personal contribution to the campaign accounts for a fraction of this total, at $200,000. This funding significantly outpaces that of his Democratic competitor, Amy Acton, a doctor and former head of the state's health department, who had raised $1.4 million.